Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 5, 2013, Pages 786-791

  Chang, Kai Ping ^a,b   Kao, Huang Kai ^b   Wu, Chih Ching ^c   Fang, Ku Hao ^a   Chang, Yu Liang ^a   Huang, Yu Chen ^a   Liu, Shiau Chin ^a   Cheng, Ming Huei ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cytokine; Head and neck; Il 6; Oral cancer; OSCC; Serum marker; Tumor marker

Indexed keywords

INTERLEUKIN 6; BIOLOGICAL MARKER;

ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; BLOOD; MORTALITY; MOUTH TUMOR; PRECANCER; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME; TUMOR VOLUME;

BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; HUMANS; INTERLEUKIN-6; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

MLCS; MLOWN;

EID: 84879301656     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599813478573     Document Type: Article

References (23)

1. Oppenheim JJ, Murphy WJ, Chertox O, Schirrmacher V, Wang JM. Prospects for cytokine and chemokine biotherapy. Clin Cancer Res. 1997;3:2682-2686.
2. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002;13:143-154.
3. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004;14:181-185.
4. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44:1093-1099.
5. Chang KP, Chang YT, Liao CT, et al. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clin Chim Acta. 2011;412:980-987.
6. St John MA, Li Y, Zhou X, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:929-935.
7. Liao CT, Chang JT, Wang HM, et al. Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer. 2006;107:337-344.
8. Liao CT, Huang SF, Chen IH, et al. Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. Ann Surg Oncol. 2009;16:159-170.
9. Chang KP, Hao SP, Liu CT, et al. Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol. 2007;43: 345-351.
10. Fang KH, Kao HK, Cheng MH, et al. Histological differentiation of primary oral squamous cell carcinomas in an area of betel quid chewing prevalence. Otolaryngol Head Neck Surg. 2009;141:743-749.
11. Chang KP, Kao HK, Liang Y, et al. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. Ann Surg Oncol. 2010;17: 1945-1956.
12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
13. Chang KP, Chang YT, Wu CC, et al. Multiplexed immunobeadbased profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck. 2011;33:886-897.
14. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750-757.
15. Nakano Y, Kobayashi W, Sugai S, Kimura H, Yagihashi S. Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma. Jpn J Cancer Res. 1999;90: 858-866.
16. DiNatale BC, Schroeder JC, Perdew GH. Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Mol Carcinog. 2011;50: 173-183.
17. Vucicevic Boras V, Cikes N, Lukac J, Virag M, Cekic-Arambasin A. Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol. 2005;54:569-573.
18. SahebJamee M, Eslami M, Atarbashi Moghadam F, Sarafnejad A. Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008;13:E292-E295.
19. Kayamori K, Sakamoto K, Nakashima T, et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol. 2010;176:968-980.
20. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1-10.
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1-20.
22. Heikkila K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008;44:937-945.
23. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012;30:1005-1014.